Type 2 diabetes and the skeleton: new insights into sweet bones

被引:241
作者
Shanbhogue, Vikram V. [1 ,2 ]
Mitchell, Deborah M. [3 ]
Rosen, Clifford J. [4 ]
Bouxsein, Mary L. [5 ,6 ]
机构
[1] Univ Southern Denmark, Odense Univ Hosp, Dept Endocrinol, Odense, Denmark
[2] Univ Southern Denmark, Inst Clin Res, Odense, Denmark
[3] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA
[4] Maine Med Ctr, Res Inst, Ctr Clin & Translat Res, Scarborough, ME USA
[5] Beth Israel Deaconess Med Ctr, Ctr Adv Orthopaed Studies, Boston, MA 02215 USA
[6] Harvard Univ, Sch Med, Boston, MA USA
基金
美国国家卫生研究院;
关键词
DEPENDENT INSULINOTROPIC PEPTIDE; PREVALENT VERTEBRAL DEFORMITIES; ISLET AMYLOID POLYPEPTIDE; GLYCATION END-PRODUCTS; COLLAGEN CROSS-LINKING; MINERAL DENSITY; FRACTURE RISK; POSTMENOPAUSAL WOMEN; OLDER WHITE; IN-VIVO;
D O I
10.1016/S2213-8587(15)00283-1
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Substantial evidence shows that skeletal fragility should be considered among the complications associated with type 2 diabetes. Individuals with type 2 diabetes have increased fracture risk, despite normal bone mineral density (BMD) and high BMI-factors that are generally protective against fractures. The mechanisms underlying skeletal fragility in diabetes are not completely understood, but are multifactorial and likely include effects of obesity, hyperglycaemia, oxidative stress, and accumulation of advanced glycation end products, leading to altered bone metabolism, structure, and strength. Clinicians should be aware that BMD measurements underestimate fracture risk in people with type 2 diabetes, and that new treatments for diabetes, with neutral or positive effects on skeletal health, might play a part in the management of diabetes in those at high risk of fracture. Data for the optimum management of osteoporosis in patients with type 2 diabetes are scarce, but in the absence of evidence to the contrary, physicians should follow guidelines established for postmenopausal osteoporosis.
引用
收藏
页码:159 / 173
页数:15
相关论文
共 137 条
[1]
Correlations between insulin sensitivity and bone mineral density in non-diabetic men [J].
Abrahamsen, B ;
Rohold, A ;
Henriksen, JE ;
Beck-Nielsen, H .
DIABETIC MEDICINE, 2000, 17 (02) :124-129
[2]
Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra [J].
Allen, M. R. ;
Gineyts, E. ;
Leeming, D. J. ;
Burr, D. B. ;
Delmas, P. D. .
OSTEOPOROSIS INTERNATIONAL, 2008, 19 (03) :329-337
[3]
Bone Structure and Estimated Bone Strength in Obese Patients Evaluated by High-Resolution Peripheral Quantitative Computed Tomography [J].
Andersen, Stine ;
Frederiksen, Katrine Diemer ;
Hansen, Stinus ;
Brixen, Kim ;
Gram, Jeppe ;
Stoving, Rene Klinkby .
CALCIFIED TISSUE INTERNATIONAL, 2014, 95 (01) :19-28
[4]
[Anonymous], COCHRANE DATABASE SY
[5]
Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes [J].
Ardawi, Mohammed-Salleh M. ;
Akhbar, Daad H. ;
AlShaikh, Abdulrahman ;
Ahmed, Maimoona M. ;
Qari, Mohammed H. ;
Rouzi, Abdulrahim A. ;
Ali, Ahmed Y. ;
Abdulrafee, Adel A. ;
Saeda, Mamdouh Y. .
BONE, 2013, 56 (02) :355-362
[6]
Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity [J].
Arita, Y ;
Kihara, S ;
Ouchi, N ;
Takahashi, M ;
Maeda, K ;
Miyagawa, J ;
Hotta, K ;
Shimomura, I ;
Nakamura, T ;
Miyaoka, K ;
Kuriyama, H ;
Nishida, M ;
Yamashita, S ;
Okubo, K ;
Matsubara, K ;
Muraguchi, M ;
Ohmoto, Y ;
Funahashi, T ;
Matsuzawa, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 257 (01) :79-83
[7]
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin [J].
Bolinder, J. ;
Ljunggren, O. ;
Johansson, L. ;
Wilding, J. ;
Langkilde, A. M. ;
Sjostrom, C. D. ;
Sugg, J. ;
Parikh, S. .
DIABETES OBESITY & METABOLISM, 2014, 16 (02) :159-169
[8]
Risk of fracture in women with type 2 diabetes: The Women's Health Initiative Observational Study [J].
Bonds, Denise E. ;
Larson, Joseph C. ;
Schwartz, Ann V. ;
Strotmeyer, Elsa S. ;
Robbins, John ;
Rodriguez, Beatriz L. ;
Johnson, Karen C. ;
Margolis, Karen L. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (09) :3404-3410
[9]
Metabolic Syndrome, Aging and Involvement of Oxidative Stress [J].
Bonomini, Francesca ;
Rodella, Luigi Fabrizio ;
Rezzani, Rita .
AGING AND DISEASE, 2015, 6 (02) :109-120
[10]
A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients [J].
Borges, J. L. C. ;
Bilezikian, J. P. ;
Jones-Leone, A. R. ;
Acusta, A. P. ;
Ambery, P. D. ;
Nino, A. J. ;
Grosse, M. ;
Fitzpatrick, L. A. ;
Cobitz, A. R. .
DIABETES OBESITY & METABOLISM, 2011, 13 (11) :1036-1046